Latest News
Lilly Stock Slips Despite Mounjaro Heart Approval
Eli Lilly shares dipped 0.9% despite FDA approval for Mounjaro to cut heart risks, as investors had already priced in the news. Sales still surged 91%.
Roivant Dips 2.7% Despite FDA Nod for LISRAYA; JPMorgan Sees $2B Peak Sales
Roivant shares slipped 2.7% to $36.58 despite FDA approval of LISRAYA, the first oral treatment for dermatomyositis. JPMorgan sees peak U.S. sales exceeding $2 billion.
Kazia Therapeutics Slides 7.3% on $40M Equity Offering After Clinical Rally
Kazia Therapeutics shares dropped 7.3% after pricing a $40 million equity offering, capitalizing on a recent clinical data surge but diluting existing shareholders.
SentinelOne Stock Slides on Reduced Profit Forecast Despite Strong ARR Growth
SentinelOne shares dropped 5.9% premarket after the company lowered its full-year EPS forecast, even as Q2 revenue and ARR grew strongly.
Hormel Shares Plummet 10% on Weak Sales Outlook and Retail Volume Decline
Hormel Foods shares plunged 10% after the company lowered its full-year sales guidance and reported a 9% decline in retail volume, despite an earnings beat.
Autodesk Tumbles on Soft Q3 Profit Forecast Despite Strong Q2
Autodesk shares dropped 4.1% premarket as Q3 profit guidance fell short of expectations, even as Q2 revenue rose 16% and free cash flow grew 24%.
Build-A-Bear Stock Plunges 27% on Slashed Guidance
Build-A-Bear Workshop (BBW) shares plummeted 27.3% to $28.44 after the company slashed its fiscal 2026 outlook, citing weak e-commerce demand and a lost Walmart program.
Best Buy Stock Slides Despite Q2 Beat as Margin Pressures Mount
Best Buy (BBY) shares dropped 4.4% despite a Q2 earnings beat, as rising costs offset profit gains. Revenue grew 3.6% to $9.78B, with comps up 4.1%. FY outlook raised.
Ulta Beauty Stock Slips Despite Q2 Beat and Raised Forecast
Ulta Beauty shares slipped 1.5% premarket even after Q2 results beat estimates and 2026 guidance was raised. Sales grew 8.9% to $3.04B, with EPS of $6.55.
BioLineRx Plunges 20% on Dilutive $3.75M Offering
BioLineRx shares dropped 20% after a $3.75M offering priced at $2.78 per ADS, with warrants that could significantly increase dilution.
Elastic Stock Soars on $1.85B Backlog, Strong Guidance
Elastic's stock jumped 17.4% premarket as Q1 revenue rose 15% and RPO backlog surged 27%, signaling robust future revenue. Q2 guidance also topped expectations.
Quoin Rockets 42% on QRX003 Data, Unveils $50M Funding Plan
Quoin shares jumped 41.8% after QRX003 met its primary endpoint in an interim analysis. The company also announced a $50 million fundraising.